David Baskin Bristol Myers Squibb BMY-N COMMENT Dec 20, 2012

Recently bought on technicals. Pretty decent dividend. Sees growth coming back.

It often pops with a new drug but he doesn't like the sector. Pharma companies have not been good to invest in over the past year. He prefers companies with a medical devices component.

Stock has been hot since the summer when the new CEO took over, then they got approval for their schizophrenia drugs. (Abbvie's drug failed last month.) But BMY has fallen 9% in the past 4 weeks--maybe because of concerns over the group, not the stock. Trades at only 7.9x PE 2025, and pays a 4.4% dividend which just increased last week. The stock is dirt cheap.

It's turned around in the last 6 months under the new CEO, rallying 40%. In the face of expiring drug patents, they launched a revolutionary schizophrenia drug. He also likes the rest of their pipeline to treat cardiovascular disease and oncology. He bought shares late last year.

Shares are down, but buy more. Their new schizophrenia drug is super, and the stock pays a 4% dividend. A great CEO.

It reports Thursday. Watch for news on Cobenfy, the new schizophrenia drug in 30 years, and potentially good. And with their yield, BMY is one of his favourites.

She bought it because the industry has underperformed many years; they're facing several drugs coming off patent, but are developing new drugs they will bring to market. Trades under 9x PE and pays a 4.6% dividend. This industry will benefit greatly from AI.

They have huge oncology franchise, but face a huge patent cliff. But they have a some promising drugs. He owns this partly for the 5.6% dividend. He took shares off the table when the stock spiked earlier this year, but at current levels, he's watching the price go lower before buying again.

You're betting on their drug pipeline.

Has never been this cheap. Has high hopes for their new central nervous system drug; it if doesn't work, he will sell BMY.